trending Market Intelligence /marketintelligence/en/news-insights/trending/wcRueMBJjjXJcAgpddIO2A2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Protalix signs licensing deal for Fabry disease drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Protalix signs licensing deal for Fabry disease drug

Protalix BioTherapeutics, Inc. entered into an ex-U.S. development and commercialization agreement with Chiesi Farmaceutici SpA for PRX-102, its Fabry disease drug.

Fabry disease is a rare genetic disorder causing the buildup of a particular fatty substance in the blood vessel walls.

Under the agreement, Protalix will receive an upfront payment of $25 million and additional payments of up to $25 million. The company is also entitled to get up to $320 million of aggregate regulatory and commercial milestone payments, as well as tiered royalties.

Following marketing approvals, Protalix will continue manufacturing the drug for clinical development and commercial purposes. The company also continues to retain full rights to the drug in the U.S. market.